Pluri, Inc.
New York
New York
United States
359 articles about Pluri, Inc.
-
Pluristem Therapeutics Announces First Patient Enrollment in Phase I Clinical Trial for Treatment of Peripheral Artery Disease With PLX-PAD
7/7/2009
-
Pluristem Therapeutics Was Awarded a $1.9 Million Grant From the Office of the Chief Scientist in the Israeli Government
6/29/2009
-
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
6/16/2009
-
Pluristem Therapeutics to Present at the Second Annual Life Science Conference of The Society of Investment Professionals in Germany
6/10/2009
-
Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI) BioMed Conference
6/8/2009
-
Pluristem Therapeutics to Present at the International Society for Stem Cell Research 7th Annual Meeting
5/26/2009
-
Pluristem Therapeutics to Present at the Center for Finance Education
5/12/2009
-
Pluristem Therapeutics Announces $1.3 Million Securities Offering with Two Institutional Investors
5/6/2009
-
Pluristem Therapeutics to Present at the 2009 BIO International Convention as Part of the Israeli Delegation
5/5/2009
-
Pluristem Therapeutics Announces Major Clinical Site in North Carolina for PLX-PAD Phase-I Trial
5/5/2009
-
Pluristem Therapeutics to Present at the Tel-Aviv Stock Exchange
4/20/2009
-
Pluristem Therapeutics to Sponsor the World Conference on Regenerative Medicine
4/7/2009
-
Pluristem Therapeutics to Present at the German Equity Forum
3/31/2009
-
Pluristem Therapeutics to Present at “The Stem Cell Network” Conference
3/17/2009
-
Pluristem Therapeutics Prepares for Placental-Derived Stem Cell Clinical Trial
3/9/2009
-
Pluristem Therapeutics Receives FDA Clearance to Begin “First-In-Human” Placenta-Derived Stem Cell Clinical Trial
3/2/2009
-
Pluristem Therapeutics Collaborates with Pharmicell Europe GmbH to Distribute Pluristem’s Cell Therapy Product for Clinical Trials in Germany
2/24/2009
-
Pluristem Therapeutics to Present at Italian CREM Workshop Focused on Placental-Derived Cells
2/17/2009
-
Pluristem Therapeutics Receives Deficiency and Compliance Notice from Nasdaq
2/11/2009
-
Pluristem Therapeutics Appoints Dr. Frida Grynspan to Vice President of Research and Development
2/11/2009